Triple-negative breast cancer is the rarest form of breast cancer, yet still accounts for 15-20% of cases.1 This form of breast cancer differs from others through: the underlying tumour biology, the type of people most at risk of developing the disease, and the experiences they have during diagnosis and treatment.
By lacking the three main characteristics associated with breast cancer cells, triple-negative breast cancer represents a critical clinical challenge, and people diagnosed with the disease can be made to feel like there is little hope to combat the disease.
Women with triple-negative breast cancer are less likely to survive the first five years after diagnosis compared to those with other forms of breast cancer.2 With limited treatment options and a poorer prognosis, it is essential to continue advancing research in triple-negative breast cancer.
Roche has a long heritage of working in breast cancer, and continues to be committed to advancing research in triple-negative breast cancer to improve outcomes for people with this complex disease. With research and development we are looking towards a future where people with triple-negative breast cancer may have as many options as those with other types of breast cancer.
Yao H et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2017;8(1):1913–1924
Li X et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. 2016;161(2):279-287.